Plasma kallikrein binding proteins

Abstract

Plasma kallikrein binding proteins and methods of using such proteins are described.

1 .- 8 . (canceled) 
     
     
         9 . An isolated antibody or functional fragment thereof that binds to the active form of human plasma kallikrein, wherein the antibody or antigen binding fragment thereof comprises:
 a heavy chain variable region comprising a complementarity determining region (CDR) 1 set forth as HYIMM (SEQ ID NO: 166), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 167), and a CDR3 set forth as RRTGVPRWDDFDI (SEQ ID NO: 1177); and a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 1172), a CDR2 set forth as KASTLES (SEQ ID NO: 1173), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 1174).   
     
     
         10 . The isolated antibody or functional fragment thereof of  claim 9 , comprising:
 a heavy chain variable region set forth as EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITVY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAFRRTGVPRWDDFDIWGQGTMVT VSSASTKGPSVFPLAPSSKS (SEQ ID NO: 1801); and a light chain variable region set forth as QDIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPNLLIYKASTLESGVPSR FSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIK (SEQ ID NO: 2389).   
     
     
         11 . The isolated antibody or antigen binding fragment of  claim 9 , wherein the antibody is a full-length antibody. 
     
     
         12 . The isolated antibody of  claim 11 , wherein the antibody is an IgG antibody. 
     
     
         13 . The antigen binding fragment of  claim 11 , wherein the antibody is a soluble Fab (sFab). 
     
     
         14 . A nucleic acid(s) encoding the isolated antibody or antigen binding fragment of  claim 9 . 
     
     
         15 . A vector(s) comprising the nucleic acid(s) of  claim 14 . 
     
     
         16 . The vector(s) of  claim 15 , wherein the vector(s) is an expression vector(s). 
     
     
         17 . A host cell comprising the nucleic acid(s) of  claim 14 . 
     
     
         18 . The host cell of  claim 17 , wherein the cell is a mammalian cell. 
     
     
         19 . The host cell of  claim 18 , wherein the mammalian cell is a Chinese Hamster Ovarian (CHO) cell. 
     
     
         20 . A method of producing an antibody comprising,
 culturing the host cell of  claim 17  in a culture medium, thereby producing the antibody.   
     
     
         21 . The method of  claim 20 , further comprising purifying the antibody from the culture medium. 
     
     
         22 . A pharmaceutical composition comprising the isolated antibody or antigen binding fragment of  claim 9  and a pharmaceutically acceptable carrier. 
     
     
         23 . A method of detecting plasma kallikrein in a subject, the method comprising
 administering the isolated antibody or antigen binding fragment of  claim 9 ; and   detecting an interaction between the antibody and plasma kallikrein in the subject.   
     
     
         24 . The method of  claim 23 , wherein the antibody comprises a detectable label. 
     
     
         25 . A method of detecting plasma kallikrein in a sample, the method comprising
 contacting the sample with the isolated antibody or antigen binding fragment of  claim 9 ; and   detecting an interaction between the antibody and plasma kallikrein in the sample, if present.   
     
     
         26 . The method of  claim 25 , wherein the sample is obtained from a subject. 
     
     
         27 . The method of  claim 26 , wherein the sample is a biopsy sample.